Prime Minister Donald Tusk: Adamed’s investment is a strong example of Polish-Vietnamese cooperation
Prime Minister Donald Tusk highlighted Adamed’s investment in Vietnam as an example of cooperation that benefits both countries and supports their economic development. During the Polish-Vietnamese Business Roundtable, attended by the prime ministers of both countries, he identified the pharmaceutical industry as one of the three most promising areas of cooperation, alongside the defence and space sectors. Dr Małgorzata Adamkiewicz, MD, PhD, Co-owner of Adamed, announced the company’s continued development in Vietnam and further expansion into Asian markets.
“Adamed’s investment has been accompanied by the development of production facilities, technological modernisation and the implementation of higher quality standards. This is a good example of the model we would like to develop: Polish capital, technology and experience combined with the expertise of Vietnamese specialists and the potential of the local market,” said Prime Minister Donald Tusk.
He emphasised that cooperation in the pharmaceutical sector could include further investment, research, the development of production capabilities, and the export of medicines and medical devices to other markets in the region.
Vietnam as Adamed’s strategic growth hub in Asia
Davipharm, part of the Adamed Group since 2017, is the largest Polish direct investment in Vietnam and Southeast Asia. The Polish company operates a manufacturing facility and a research and development centre in the country.
“We want Vietnam to become our strategic growth hub in Asia, enabling us to expand into other markets across the region. The country’s dynamic development and enormous potential reinforce my belief that we should continue investing here with a view to building a long-term presence,” said Dr Małgorzata Adamkiewicz, MD, PhD, Co-owner and President of the Supervisory Board of Adamed Pharma.
The company also announced plans to develop cooperation with Vietnamese schools, universities and institutions in the areas of innovation, knowledge transfer and improving patients’ access to high-quality medicines.
Adamed highlights barriers in Vietnam
Representatives of Polish businesses discussed the barriers that make further investment and the introduction of new medicines to the market more difficult. For Adamed, these include lengthy delays in medicine registration and the lack of transition periods when regulatory changes are introduced.
“We need a stable, predictable and efficient regulatory environment,” said Michał Wieczorek, General Director of Davipharm.
Donald Tusk also addressed the need to streamline procedures.
“Large-scale industrial and technological projects require predictable regulations, transparent procedures, efficient certification processes and access to appropriate financing instruments,” the Prime Minister emphasised.
Adamed hopes that dialogue between the two countries’ administrations will help remove barriers that currently limit further investment, technology transfer and the development of pharmaceutical production in Vietnam.
Davipharm: the largest Polish direct investment in Vietnam
Adamed began investing in Vietnam in 2017, when it acquired a majority stake in Davipharm. Since 2023, Adamed has been the company’s sole owner.
Davipharm employs nearly 500 people and manufactures more than 300 products across 12 therapeutic areas. It was the first manufacturing facility in Vietnam to obtain EU-GMP certification for its high-potency drug production area, including oncology medicines. It is one of only a small number of pharmaceutical manufacturers in the country to hold this European certification, confirming compliance with the highest quality standards.